Incyte Corp.’s US approval of Pemazyre (pemigatinib) for a genetic subset of the rare bile duct cancer cholangiocarcinoma is a small economic opportunity, but one that could eventually lead to a broader label for the target fibroblast growth factor receptor 2 (FGFR2) inhibitor.
The biotech plans to make the drug available to patients immediately but needs time to shift to a virtual strategy as face-to-face detailing to doctors is largely